Recent investigations have highlighted the significance of FXR as a critical therapeutic target in NAFLD, with encouraging findings showcasing the substantial amelioration of pathological manifestations in patients with NASH upon treatment with FXR agonists [53]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.